NCT05453136View on ClinicalTrials.gov

Phase III Study of TS-142 in Patients with Insomnia

PHASE3CompletedINTERVENTIONAL
Enrollment

1,155

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

December 5, 2023

Study Completion Date

December 5, 2023

Conditions
Patients with Insomnia
Interventions
DRUG

TS-142 5 mg

Participants received repeated doses of 5 mg of TS-142 (oral tablet)

DRUG

TS-142 10 mg

Participants received repeated doses of 10 mg of TS-142 (oral tablet)

DRUG

Placebo to TS-142

Participants received repeated doses of placebo to TS-142 (oral tablet)

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY